1. Purpose
Background
Multiple reports have confirmed the early safety and efficacy of EVAR*
Secondary intervention were required in 15 to 30%:
mostly due to endoleak
the majority were treated by endovascular approach
* Brewsteret al, Ann Surg. 2006; Moore et al, J Vasc Surg. 2001
** EVAR trial, Lancet 2005; Prinsen et al, NEJM 2005

2. Purpose
Background
Persistence of endothelial lining in the aneurysm sac increased the risk of endoleak*:
in a canine model the removal of endothelium prevent recanalisation
this protective effect was decreased by the presence of patent side branches vessel
* Soulez et al, JVIR 2008

3. Purpose
Without side branches
Patent side branches

4. Purpose
Hypothesis
Simultaneous embolization and destruction of endothelium are both necessary to prevent endoleak
We need a new embolization agent:
enabling endothelial sclerosis and embolization
which can be easily injected in the aneurysm through a catheter

5. Purpose To compare efficacy of embolization: By analysis of:
by chitosan
with vs without sclerosant agent (STS)
By analysis of:
initial length of embolization
% of recanalization at D30